Significance and applications of nanoparticles in siRNA delivery for cancer therapy

Expert Review of Clinical Pharmacology

Volumn 5, Issue 4, 2012, Pages 403-412

  Ali, Hafiz Muhammad ^a   Urbinati, Giorgia ^a   Raouane, Mouna ^a   Massaad Massade, Liliane ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

cancer therapy; delivery systems; nanoparticles; siRNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; IRINOTECAN; LIPOPLEX; NANOSPHERE; SMALL INTERFERING RNA; SQUALENE; VIRUS VECTOR;

ANTISENSE THERAPY; CANCER THERAPY; COLON CARCINOMA; DRUG MECHANISM; EWING SARCOMA; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENE THERAPY; GLIOBLASTOMA; HUMAN; MICELLE; NASOPHARYNX TUMOR; NEUROECTODERM TUMOR; NONHUMAN; ORTHOTOPIC GLIOBLASTOMA; OVARY CARCINOMA; PRIMITIVE NEUROECTODERMAL TUMOR; REVIEW; RNA INTERFERENCE; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NANOPARTICLES; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, SMALL INTERFERING;

EID: 84866053945     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.33     Document Type: Review

References (74)

1. Prieur A, Tirode F, Cohen P, Delattre O. EWS/fli-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 24(16), 7275-7283 (2004).
2. Maksimenko A, Polard V, Villemeur M et al. In vivo potentialities of EWS-fli-1 targeted antisense oligonucleotides-nanospheres complexes. Ann. NY Acad. Sci. 1058, 52-61
3. Raouane M, Desmaele D, Gilbert-Sirieix M et al. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. J. Med. Chem. 54(12), 4067-4076 (2011).
4. • Discusses how new efficient squalene nanoparticles (NPs) are useful to deliver siRNA to their target, leading to significant mRNA and protein inhibition. 4 Yoshizawa T, Hattori Y, Hakoshima M, Koga K, Maitani Y. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur. J. Pharm. Biopharm. 70(3), 718-725 (2008).
5. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release 129(2), 107-116 (2008).
6. Schiffelers RM, Ansari A, Xu J et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32(19), e149
7. Cubillos-Ruiz JR, Engle X, Scarlett UK et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J. Clin. Invest. 119(8), 2231-2244 (2009).
8. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem. Biophys. Res. Commun. 311(3), 786-792 (2003).
9. Aigner A. Cellular delivery in vivo of siRNA-based therapeutics. Curr. Pharm. Des. 14(34), 3603-3619 (2008).
10. Halder J, Kamat AA, Landen CN Jr et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 12(16), 4916-4924
11. Soutschek J, Akinc A, Bramlage B et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432(7014), 173-178
12. Kuo WT, Huang HY, Huang YY. Intracellular trafficking, metabolism and toxicity of current gene carriers. Curr. Drug Metab. 10(8), 885-894 (2009).
13. Akhtar S, Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol. Sci. 18(1), 12-18 (1997).
14. Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl Acad. Sci. USA 85(14), 5011-5015 (1988).
15. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther. 13(6), 464-477 (2006).
16. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: A progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6(6), 443-453 (2007).
17. Fuchs U, Borkhardt A. The application of siRNA technology to cancer biology discovery. Adv. Cancer Res. 96, 75-102
18. De Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13(4), 431-456 (2007).
19. Ryther RC, Flynt AS, Phillips JA 3rd, Patton JG. siRNA therapeutics: Big potential from small RNAs. Gene Ther. 12(1), 5-11 (2005).
20. Underhill DM, Ozinsky A. Phagocytosis of microbes: Complexity in action. Annu. Rev. Immunol. 20, 825-852 (2002).
21. Juliano R, Bauman J, Kang H, Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 6(3), 686-695 (2009).
22. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760 (2002).
23. Zámecník J, Vargová L, Homola A, Kodet R, Syková E. Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours. Neuropathol. Appl. Neurobiol. 30(4), 338-350 (2004).
24. Dai Z, Zhang Q, Wang Z, Zhang Z, Guo P, Zhao D. Hemagglutinating virus of Japan envelope (HVJ-E) can enhance the immune responses of swine immunized with killed PRRSV vaccine. Biochem. Biophys. Res. Commun. 415(1), 1-5 (2011).
25. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114(1), 100-109 (2006).
26. Mowa MB, Crowther C, Arbuthnot P. Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators. Expert Opin. Drug Deliv. 7(12), 1373-1385
27. Wang J, Faust SM, Rabinowitz JE. The next step in gene delivery: Molecular engineering of adeno-associated virus serotypes. J. Mol. Cell. Cardiol. 50(5), 793-802 (2011).
28. Zaldumbide A, Hoeben RC. How not to be seen: Immune-evasion strategies in gene therapy. Gene Ther. 15(4), 239-246 (2008).
29. Chou LY, Ming K, Chan WC. Strategies for the intracellular delivery of nanoparticles. Chem. Soc. Rev. 40(1), 233-245 (2011).
30. Kievit FM, Veiseh O, Bhattarai N et al. PEI-PEG-chitosan copolymer coated iron oxide nanoparticles for safe gene delivery: Synthesis, complexation, and transfection. Adv. Funct. Mater. 19(14), 2244-2251
31. Yezhelyev MV, Qi L, O'Regan RM, Nie S, Gao X. Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J. Am. Chem. Soc. 130(28), 9006-9012 (2008).
32. Derfus AM, Chen AA, Min DH, Ruoslahti E, Bhatia SN. Targeted quantum dot conjugates for siRNA delivery. Bioconjug. Chem. 18(5), 1391-1396 (2007).
33. Stoltenburg R, Reinemann C, Strehlitz B. SELEX - a revolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 24(4), 381-403 (2007).
34. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10(11), 3667-3677
35. Carot ML, Torresi RM, Garcia CD, Esplandiu MJ, Giacomelli CE. Electrostatic and hydrophobic interactions involved in CNT biofunctionalization with short ss-DNA. J. Phys. Chem. C. Nanomater. Interfaces 114(10), 4459-4465 (2010).
36. Kakizawa Y, Furukawa S, Ishii A, Kataoka K. Organic-inorganic hybrid-nanocarrier of siRNA constructing through the selfassembly of calcium phosphate and PEG-based block aniomer. J. Control. Release 111(3), 368-370 (2006).
37. de Wolf HK, Snel CJ, Verbaan FJ, Schiffelers RM, Hennink WE, Storm G. Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. Int. J. Pharm. 331(2), 167-175 (2007).
38. Verbaan FJ, Oussoren C, Snel CJ, Crommelin DJ, Hennink WE, Storm G. Steric stabilization of poly(2- (dimethylamino)ethyl methacrylate)-based polyplexes mediates prolonged circulation and tumor targeting in mice. J. Gene Med. 6(1), 64-75 (2004).
39. de Martimprey H, Bertrand JR, Fusco A et al. siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res. 36(1), e2
40. Dubey PK, Mishra V, Jain S, Mahor S, Vyas SP. Liposomes modified with cyclic RGD peptide for tumor targeting. J. Drug Target. 12(5), 257-264 (2004).
41. Noguchi Y, Wu J, Duncan R et al. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn J. Cancer Res. 89(3), 307-314
42. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines. J. Drug Target. 15(7-8), 457-464 (2007).
43. Oliveira S, van Rooy I, Kranenburg O, Storm G, Schiffelers RM. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int. J. Pharm. 331(2), 211-214
44. Cho YW, Kim JD, Park K. Polycation gene delivery systems: Escape from endosomes to cytosol. J. Pharm. Pharmacol. 55(6), 721-734 (2003).
45. Wu SY, McMillan NA. Lipidic systems for in vivo siRNA delivery. AAPS J. 11(4), 639-652 (2009).
46. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009).
47. Frank-Kamenetsky M, Grefhorst A, Anderson NN et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci. USA 105(33), 11915-11920 (2008).
48. Raouane M, Desmaële D, Urbinati G, Massaad-Massade L, Couvreur P. Lipid conjugated oligonucleotides: A useful strategy for delivery. Bioconjug. Chem. doi:10.1021/bc200422w (2012) (Epub ahead of print).
49. de Martimprey H, Bertrand JR, Malvy C, Couvreur P, Vauthier C. New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma. Pharm. Res. 27(3), 498-509
50. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 327(4), 761-766 (2003).
51. Landen CN Jr, Chavez-Reyes A, Bucana C et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65(15), 6910-6918 (2005).
52. Kataoka K, Itaka K, Nishiyama N, Yamasaki Y, Oishi M, Nagasaki Y. Smart polymeric micelles as nanocarriers for oligonucleotides and siRNA delivery. Nucleic Acids Symp. Ser. (Oxf.) 49, 17-18 (2005).
53. Arnida, Nishiyama N, Kanayama N, Jang WD, Yamasaki Y, Kataoka K. PEGylated gene nanocarriers based on block catiomers bearing ethylenediamine repeating units directed to remarkable enhancement of photochemical transfection. J. Control. Release 115(2), 208-215 (2006).
54. Oishi M, Nagasaki Y, Itaka K, Nishiyama N, Kataoka K. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. 127(6), 1624-1625 (2005).
55. Hassani Z, Lemkine GF, Erbacher P et al. Lipid-mediated siRNA delivery downregulates exogenous gene expression in the mouse brain at picomolar levels. J. Gene Med. 7(2), 198-207 (2005).
56. Rudolph C, Schillinger U, Ortiz A et al. Aerosolized nanogram quantities of plasmid DNA mediate highly efficient gene delivery to mouse airway epithelium. Mol. Ther. 12(3), 493-501 (2005).
57. Höbel S, Koburger I, John M et al. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J. Gene Med. 12(3), 287-300
58. Günther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur. J. Pharm. Biopharm. 77(3), 438-449 (2011).
59. Plank C, Mechtler K, Szoka FC Jr, Wagner E. Activation of the complement system by synthetic DNA complexes: A potential barrier for intravenous gene delivery. Hum. Gene Ther. 7(12), 1437-1446 (1996).
60. Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud A, Sgouros G. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int. J. Cancer 112(4), 713-721
61. Li SD, Huang L. Stealth nanoparticles: High density but sheddable PEG is a key for tumor targeting. J. Control. Release 145(3), 178-181 (2010).
62. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9(8), 615-627 (2010).
63. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl Cancer Inst. 98(5), 335-344 (2006).
64. Bartlett DW, Davis ME. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem. 18(2), 456-468 (2007).
65. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt 1), 6387-6392 (1986).
66. Derfus AM, Chan WCW, Bhatia SN. intracellular delivery of quantum dots for live cell labeling and organelle tracking. Adv. Mater. 16(12), 961-966 (2004).
67. Lee Y, Koo H, Lim YB, Lee Y, Mo H, Park JS. New cationic lipids for gene transfer with high efficiency and low toxicity: T-shape cholesterol ester derivatives. Bioorg. Med. Chem. Lett. 14(10), 2637-2641 (2004).
68. Percot A, Briane D, Coudert R et al. A hydroxyethylated cholesterol-based cationic lipid for DNA delivery: Effect of conditioning. Int. J. Pharm. 278(1), 143-163 (2004).
69. Noguchi S, Hirashima N, Furuno T, Nakanishi M. Remarkable induction of apoptosis in cancer cells by a novel cationic liposome complexed with a bcl-2 antisense oligonucleotide. J. Control. Release 88(2), 313-320 (2003).
70. Reddy LH, Renoir JM, Marsaud V, Lepetre-Mouelhi S, Desmaële D, Couvreur P. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. Mol. Pharm. 6(5), 1526-1535
71. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836), 494-498 (2001).
72. Lambert G, Fattal E, Pinto-Alphandary H, Gulik A, Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm. Res. 17(6), 707-714 (2000).
73. Grzelinski M, Urban-Klein B, Martens T et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 17(7), 751-766 (2006).
74. Koga K, Hattori Y, Komori M et al. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis. Cancer Sci. 101(4), 941-947 (2010).